UPDATE: Due to your abundant generosity, we have started the first round of manufacturing! We now need to raise $300,000 more to fund a toxicology study, after which we need $2.2M to manufacture the materials needed for the clinical trial.

All contributions made here go directly toward paying those bills.

Our story:

In February 2025, we were devastated to learn our four year old George was born with a neurodegenerative disease called CMT4C. It is gradually deteriorating his peripheral nerves, and without treatment the disease will render him severely disabled in a few years.

Out of that darkness, we were encouraged to learn of a decade-long pre-clinical study (funded by the NIH, the CMTA, and the MDA) that demonstrated the efficacy of an intrathecally delivered AAV-mediated gene therapy. The data showed treatment could not only stop the progression of George's condition, but even reverse some of the degeneration if administered early enough.

Now, funding is needed to advance the gene therapy toward clinical trials and FDA approval. Project Foresee is the fundraising effort accelerating this development.

Your contributions will fund drug manufacturing, preclinical toxicology studies, and the clinical trial costs themselves.

Every contribution brings us closer to stopping the progression of this cruel disease for George and the thousands of other Americans with CMT4C, many of whom are young children. The sooner George has access to this drug, the more function will be preserved for the rest of his life.